Circadian to fund new antisense Alzheimer's project
29 November, 2002 by Graeme O'NeillMelbourne biomedical company Circadian Technologies has announced it will fund a project at Melbourne University to develop an antisense therapy for Alzheimer's disease.
Genetic Solutions wins the race for the tenderness test
28 November, 2002 by Pete YoungThe race to launch the first commercial DNA test kit identifying cattle which carry a gene associated with meat tenderness has been won by Australian agbiotech Genetic Solutions.
Carn the blues: Florigene aiming for horticulture's highest prize
28 November, 2002 by Graeme O'NeillRoses are red, and Melbourne biotech company Florigene wishes that violets were blue -- if they were, it would already have produced horticulture's most elusive prize: the world's first blue rose.
Local experts critical of proposed mouse chimera project
28 November, 2002 by Graeme O'NeillA proposed US experiment to produce a mouse for testing the organ- or tissue-forming capacity capabilities of human embryonic stem cells should not proceed -- at least, not with totipotent human ES cells, according to a leading Australian stem cell expert.
Science must help society, conference hears
27 November, 2002 by Melissa TrudingerA scientific call for action to provide solutions for disease problems in developing countries was the topic of the Merck Sharp and Dohme Lecture at the opening of the first Australian Health and Medical Research Congress in Melbourne this week.
VRI to use Proteome Systems platform to develop diagnostics
27 November, 2002 by Melissa TrudingerVRI BioMedical and Proteome Systems have signed a non-binding heads of agreement for a collaboration to develop some of VRI's diagnostic tests as point-of-care applications using Proteome Systems' proprietary diagnostic test platform.
High-profile agreements give Ambri global clout
26 November, 2002 by Pete YoungSydney biosensor specialist Ambri is leveraging newly-forged ties with two high-profile US corporates to negotiate lucrative R&D contracts with the US military.
New report pulls back the curtain on SA biotech
26 November, 2002 by Melissa TrudingerThe secrets of the South Australian bioscience sector have been revealed in a survey released last week by BioInnovation SA, the government-supported biotech industry development team.
Peplin swaps skin with Allergan
26 November, 2002 by Graeme O'NeillBrisbane's Peplin Biotech and California-based dermatology products specialist Allergan have swapped skin on a deal to bring Peplin's promising anti-cancer compound PEP005 to the skin-cancer market.
Healthy deal-flow sparks pSivida share surge
25 November, 2002 by Pete YoungA sudden surge in pSivida's share price this month focused attention on the biomaterials company's growing string of promising alliances.
Prima successful in fundraising
22 November, 2002 by Melissa TrudingerPrima Biomed has become the latest biotech company to successfully raise additional funds through a private placement to institutional and professional investors.
The future of beef is bioactive
22 November, 2002 by Graeme O'NeillFinicky beefeater Jack Sprat and his lipophilic wife would be amazed at what the meat industry is doing these days with the bits neither would eat.
GroPep debt-free by the end of 2002, company chairman says
22 November, 2002 by Melissa TrudingerAdelaide-based biotech company GroPep pre-empted the complaints of its shareholders at its annual general meeting yesterday, with chairman Richard England noting at the beginning of his speech that the year was the worst in the company's history.
Green light for EpiTan IIb trial
21 November, 2002 by Melissa TrudingerEpiTan has received approval from the ethics committee at the Royal Adelaide Hospital to conduct part of its phase IIb clinical trial there for its melanin-producing drug Melanotan.
Flinders Bio to expand business
21 November, 2002 by Melissa TrudingerFlinders University spin-off Flinders Bioremediation is continuing to expand its business operations despite the recent loss of founder and managing director Dr Nick McClure, who passed away in September.
